摘要
<b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.</span><b> </b><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"></span></b><b> </b><span style="font-family:Verdana;">Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hos</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">pital Affiliated to Hebei North </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">University</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> from February 2017 to August 2019 we</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">re </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">selected. They were randomly divided into observation group and control gro</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">up, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. <b></b></span><b><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"></span></b><span style="font-family:Verdana;"> The rate of symp</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">tom relief was 86.11% in the observation group and 94.44% in the control</span><span><span style="font-family:Verdana;"> group, P < 0.05, which was statistically significant. Rifampin was more helpful than rifapentine in relieving clinical symptoms</span><span style="font-family:Verdana;">. The lesion absorption rate was 77.79% in the observation group and 88.89% in the control group, P < 0.05, and the difference was statistically significant. Rifampin was more beneficial to the absorption of TB lesions than rifapentine. The incidence of adverse reactions in the observation group was 16.67% much lower than that in the control group, which was 38.89%, indicating that the adverse reactions of rifapentine were less. <b></b></span><b><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"></span></b></span><b> </b><span style="font-family:Verdana;">Rifampicin is superior to rifapentine in clinical symptom relief and lesion absorption, but the incidence of adverse reactions is high.</span></span></span></span>
<b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.</span><b> </b><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"></span></b><b> </b><span style="font-family:Verdana;">Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hos</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">pital Affiliated to Hebei North </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">University</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> from February 2017 to August 2019 we</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">re </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">selected. They were randomly divided into observation group and control gro</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">up, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. <b></b></span><b><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"></span></b><span style="font-family:Verdana;"> The rate of symp</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">tom relief was 86.11% in the observation group and 94.44% in the control</span><span><span style="font-family:Verdana;"> group, P < 0.05, which was statistically significant. Rifampin was more helpful than rifapentine in relieving clinical symptoms</span><span style="font-family:Verdana;">. The lesion absorption rate was 77.79% in the observation group and 88.89% in the control group, P < 0.05, and the difference was statistically significant. Rifampin was more beneficial to the absorption of TB lesions than rifapentine. The incidence of adverse reactions in the observation group was 16.67% much lower than that in the control group, which was 38.89%, indicating that the adverse reactions of rifapentine were less. <b></b></span><b><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"></span></b></span><b> </b><span style="font-family:Verdana;">Rifampicin is superior to rifapentine in clinical symptom relief and lesion absorption, but the incidence of adverse reactions is high.</span></span></span></span>
作者
Weijia Lin
Yaping Zhang
Zhi Liu
Ping Feng
Zhihua Zhang
Xiulong Zhang
Weijia Lin;Yaping Zhang;Zhi Liu;Ping Feng;Zhihua Zhang;Xiulong Zhang(Department of Respiratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China;Department of Orthopedic Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China)